Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients.

摘要: Abstract Objective: To compare volume therapy with HES 130/0.4, a new hydroxyethylstarch (HES) solution gelatin-based fluid replacement strategy. Design: Prospective, randomized, safety study. Setting: Urban, university-affiliated hospital (single institution). Participants: Forty-two patients undergoing elective cardiac surgery. Interventions: Patients were prospectively randomized into 2 groups: In group 1 (n = 21), gelatin was given perioperatively for support until the 1st postoperative day to keep central venous pressure (CVP) between 10 and 14 mmHg; in 21) 130/0.4 administered using same protocol as 1. Measurements Main Results: Standard coagulation variables modified thromboelastography (TEG ® ) used. Using different activators extrinsic intrinsic activation heparin inactivation by heparinase, onset of (coagulation time), kinetics clot formation (clot maximum firmness measured. performed after induction anesthesia (T0), at end surgery (T1), 4 hours (T2), on morning (T3). A total 3310 ± 810 mL 3070 570 used groups during study period. The did not differ regard bleeding or use packed red blood cells fresh frozen plasma. similar groups. All TEG within normal range baseline. Coagulation time data significantly elevated intensive care unit, without showing specific differences Intrinsic heparinase times remained higher No seen HES-treated gelatin-treated patients. Conclusions: Volume preparation safe surgical is an alternative plasma substitute treat deficits. Copyright © 2001 W.B. Saunders Company